Hartmut Goldschmidt

Hartmut Goldschmidt

UNVERIFIED PROFILE

Are you Hartmut Goldschmidt?   Register this Author

Register author
Hartmut Goldschmidt

Hartmut Goldschmidt

Publications by authors named "Hartmut Goldschmidt"

Are you Hartmut Goldschmidt?   Register this Author

100Publications

2131Reads

Cell-based immunotherapy approaches for multiple myeloma.

Br J Cancer 2018 Dec 6. Epub 2018 Dec 6.

Department of Hematology, Oncology and Rheumatology, Heidelberg University, Heidelberg, Germany.

View Article
December 2018

Navigating the treatment landscape in multiple myeloma: which combinations to use and when?

Ann Hematol 2018 Nov 23. Epub 2018 Nov 23.

INSERM, UMR_S 938, Proliferation and Differentiation of Stem Cells, Paris, 75012, France.

View Article
November 2018

Chemotherapy-induced peripheral neuropathy: evidence from genome-wide association studies and replication within multiple myeloma patients.

BMC Cancer 2018 Aug 15;18(1):820. Epub 2018 Aug 15.

Division of Molecular Genetic Epidemiology, German cancer research center (DKFZ), Im Neuenheimer Feld 580, DE-69120, Heidelberg, Germany.

View Article
August 2018

Cytogenetic abnormalities in monoclonal gammopathy of undetermined significance.

Leukemia 2018 Jul 6. Epub 2018 Jul 6.

Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.

View Article
July 2018

Going the distance: Are we losing patients along the multiple myeloma treatment pathway?

Crit Rev Oncol Hematol 2018 Jun 29;126:19-23. Epub 2018 Mar 29.

Department of Internal Medicine V, University Hospital Heidelberg, and National Center for Tumor Diseases (NCT), Heidelberg, Germany.

View Article
June 2018

Cytogenetic aberrations in multiple myeloma are associated with shifts in serum immunoglobulin isotypes distribution and levels.

Haematologica 2018 Apr 1;103(4):e162-e164. Epub 2018 Feb 1.

Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

View Article
April 2018

Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.

J Clin Oncol 2018 Mar 17;36(8):728-734. Epub 2018 Jan 17.

David S. Siegel, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ; Meletios A. Dimopoulos, National and Kapodistrian University of Athens, Athens, Greece; Heinz Ludwig, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria; Thierry Facon, Hôpital Claude Huriez, Centre Hospitalier Régional Universitaire de Lille, Lille, France; Hartmut Goldschmidt, Heidelberg Medical University and National Center of Tumor Diseases, Heidelberg, Germany; Andrzej Jakubowiak, University of Chicago Medicine, Chicago, IL; Jesus San-Miguel, Clinica Universidad de Navarra-Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Centro de Investigación Biomédica en Red de Cáncer, Pamplona, Spain; Mihaela Obreja and Julie Blaedel, Amgen, Thousand Oaks, CA; and A. Keith Stewart, Mayo Clinic, Scottsdale, AZ.

View Article
March 2018

A systematic classification of death causes in multiple myeloma.

Blood Cancer J 2018 03 8;8(3):30. Epub 2018 Mar 8.

Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.

View Article
March 2018

Bortezomib-induced peripheral neuropathy: A genome-wide association study on multiple myeloma patients.

Hematol Oncol 2018 Feb 20;36(1):232-237. Epub 2017 Mar 20.

Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

View Article
February 2018

Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice.

Hematol Oncol 2018 Feb 7;36(1):210-216. Epub 2017 Jul 7.

Department of Hematology, Oncology and Rheumatology, University of Heidelberg, Heidelberg, Germany.

View Article
February 2018

Therapeutic monoclonal antibodies in combination with pomalidomide can overcome refractoriness to both agents in multiple myeloma: A case-based approach.

Hematol Oncol 2018 Feb 25;36(1):258-261. Epub 2017 Aug 25.

Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.

View Article
February 2018

Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome.

Blood Cancer J 2018 02 15;8(2):22. Epub 2018 Feb 15.

Department of Pathology, The University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City, 52242, Iowa, USA.

View Article
February 2018

Platelet Count before Peripheral Blood Stem Cell Mobilization Is Associated with the Need for Plerixafor But Not with the Collection Result.

Transfus Med Hemother 2018 Jan 4;45(1):24-31. Epub 2017 Oct 4.

Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, German Red Cross Blood Service Baden-Württemberg - Hesse, Mannheim, Germany.

View Article
January 2018

Meeting report of the 6th Heidelberg Myeloma Workshop: current status and developments in diagnosis and therapy of multiple myeloma.

J Cancer Res Clin Oncol 2017 Dec 26;143(12):2521-2526. Epub 2017 Jun 26.

Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.

View Article
December 2017

Comparison of Different Stem Cell Mobilization Regimens in AL Amyloidosis Patients.

Biol Blood Marrow Transplant 2017 Nov 25;23(11):1870-1878. Epub 2017 Jul 25.

Department of Hematology, Oncology and Rheumatology, Heidelberg University, Germany; Amyloidosis Center, Heidelberg University, Germany.

View Article
November 2017

Quantitative analysis of F-NaF dynamic PET/CT cannot differentiate malignant from benign lesions in multiple myeloma.

Am J Nucl Med Mol Imaging 2017 1;7(4):148-156. Epub 2017 Sep 1.

Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ)Heidelberg, Germany.

View Article
September 2017

Diagnosis and treatment of multiple myeloma in Germany: analysis of a nationwide multi-institutional survey.

Ann Hematol 2017 Jun 13;96(6):987-993. Epub 2017 Apr 13.

Medizinische Klinik V, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.

View Article
June 2017

[Current Aspects in Diagnosis and Therapy of Plasma Cell Myeloma].

Dtsch Med Wochenschr 2017 Jun 31;142(11):800-804. Epub 2017 May 31.

Medizinische Klinik V, Universitätsklinikum Heidelberg.

View Article
June 2017

Storage Duration of Autologous Stem Cell Preparations Has No Impact on Hematopoietic Recovery after Transplantation.

Biol Blood Marrow Transplant 2017 Apr 21;23(4):684-690. Epub 2016 Dec 21.

Department of Medicine V, Heidelberg University, Heidelberg, Germany; Institute of Transfusion Medicine and Immunology, German Red Cross Blood Service Baden-Württemberg-Hessen, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. Electronic address:

View Article
April 2017

Potential therapeutic targets in plasma cell disorders: A flow cytometry study.

Cytometry B Clin Cytom 2017 03 3;92(2):145-152. Epub 2016 Feb 3.

Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.

View Article
March 2017

Genetic Susceptibility to Bortezomib-Induced Peripheral Neuroropathy: Replication of the Reported Candidate Susceptibility Loci.

Neurochem Res 2017 Mar 16;42(3):925-931. Epub 2016 Jul 16.

Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

View Article
March 2017

Galectin-8 enhances adhesion of multiple myeloma cells to vascular endothelium and is an adverse prognostic factor.

Glycobiology 2016 10 10;26(10):1048-1058. Epub 2016 Jun 10.

Clinical Cooperation Unit Applied Tumor Immunity, Deutsches Krebsforschungszentrum, 69120 Heidelberg, Germany

View Article
October 2016

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

N Engl J Med 2016 10;375(14):1319-1331

From the National and Kapodistrian University of Athens, Athens (M.A.D.); Institut Català d'Oncologia, Institut Josep Carreras, Hospital Germans Trias I Pujol, Barcelona (A.O.), and Clínica Universidad de Navarra-Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Pamplona (J.S.-M.) - both in Spain; Karolinska Institute and the Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm (H.N.); Tom Baker Cancer Centre, University of Calgary, Calgary, AB (N.J.B.), and the Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto (D.R.) - both in Canada; Levine Cancer Institute-Carolinas HealthCare System, Charlotte, NC (S.Z.U.); the Department of Haematology, University College London Hospitals NHS Trust, London (N.R.); the Department of Lymphoma-Myeloma, University of Texas M.D. Anderson Cancer Center, Houston (R.Z.O.); the Department of Hematology and Stem Cell Transplantation, Poznan University of Medical Sciences, Poznan, Poland (M.K.); the Department of Hematology, Japanese Red Cross Medical Center, Tokyo (K.S.); Vejle Hospital and University of Southern Denmark, Vejle (T.P.), and Genmab, Copenhagen (S.L.) - both in Denmark; the Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea (S.-S.Y.); the Hematology Department, Hadassah-Hebrew University Medical Center, Jerusalem (D.B.Y.); Dana-Farber Cancer Institute, Harvard Medical School, Boston (P.G.R.); University Hospital Heidelberg and the German Cancer Research Center, Heidelberg, Germany (H.G.); Janssen Research and Development, Spring House, PA (N.Z.K., L.O., C.C., X.Q., M.G., T.A.); and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France (P.M.).

View Article
October 2016

Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes.

Blood 2016 09 25;128(9):1226-33. Epub 2016 Jul 25.

Max-Eder Group "Experimental Therapies for Hematologic Malignancies," Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany; Department of Internal Medicine V, and.

View Article
September 2016

Management of high-risk Myeloma: an evidence-based review of treatment strategies.

Expert Rev Hematol 2016 Aug 4;9(8):753-65. Epub 2016 Jul 4.

a Department of Hematology , University Hospital of Heidelberg , Heidelberg , Germany.

View Article
August 2016

Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study.

Blood 2016 07 2;128(4):594-602. Epub 2016 Jun 2.

Amyloidosis Center, and Division of Hematology/Oncology/Rheumatology, Department of Internal Medicine, University of Heidelberg, Heidelberg, Germany;

View Article
July 2016

International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment.

J Clin Oncol 2016 05 14;34(13):1544-57. Epub 2016 Mar 14.

Meletios A. Dimopoulos, Efstathios Kastritis, and Evangelos Terpos, National and Kapodistrian University of Athens, Athens, Greece; Pieter Sonneveld, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands; Nelson Leung and S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; Robert Z. Orlowski, The University of Texas MD Anderson Cancer Center, Houston, TX; David H. Vesole, Hackensack University Medical Center, Hackensack, NJ; Paul G. Richardson, Dana-Farber Cancer Institute, Boston, MA; Brian G.M. Durie, Samuel Oschin Cancer Center, Los Angeles, CA; Giampaolo Merlini, Scientific Institute Policlinico San Matteo and University of Pavia, Pavia; Antonio Palumbo, University of Torino, Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino; Michele Cavo, Bologna University School of Medicine, S.Orsola's University Hospital, Bologna, Italy; Heinz Ludwig, Wilhelminenspital, Vienna, Austria; Hartmut Goldschmidt, University Hospital and National Center for Tumor Diseases Heidelberg, Heidelberg; Hermann Einsele, Wuerzburg University Medical Center, Wuerzburg, Germany; Douglas Joshua, Royal Prince Alfred Hospital, Sydney University Medical School, Sydney, New South Wales, Australia; Raymond Powles, Cancer Centre London, London, United Kingdom; Laurent Garderet, Saint Antoine Hospital & University of "Pierre et Marie Curie" Paris-6, Paris; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France; and Jesús San Miguel, Clínica Universidad de Navarra/CIMA, Navarra, Spain.

View Article
May 2016

Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition.

Blood 2016 04 16;127(17):2155-7. Epub 2016 Feb 16.

Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany; and.

View Article
April 2016

Chetomin, targeting HIF-1α/p300 complex, exhibits antitumour activity in multiple myeloma.

Br J Cancer 2016 Mar 11;114(5):519-23. Epub 2016 Feb 11.

Institute of Human Genetics, CNRS-UPR1142, Montpellier F-34396, France.

View Article
March 2016